Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.91 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.91 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.91 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | HTR2C | P28335 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | POLB | P06746 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.91 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.91 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine SCHEMBL27510472 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL3050622 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL28275981 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Endo-Atropine SCHEMBL29555014 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Hyoscyamine SCHEMBL34273 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL1411666 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31133 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL2406485 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34274 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34275 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427808-B1 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION | ADVERUM BIOTECHNOLOGIES INC (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629360-B2 | Ophthalmic composition | Sydnexis, Inc. (US) | 2026-05-19 | — | — | US | claimed |
| US-20260083720-A1 | Childhood Atropine For Myopia Progression | VYLUMA INC. (US) | 2026-03-26 | — | — | US | claimed |
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4674483-A2 | COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION | Adverum Biotechnologies, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4654948-A1 | HYDROGELS CONTAINING ATROPINE | Universidade de Santiago de Compostela (ES) | 2025-12-03 | — | — | EP | claimed |
| US-20250288575-A1 | EYE DROP COMPOSITION FOR PREVENTION OR TREATMENT OF OPHTHALMIC DISEASES AND PREPARATION METHOD THEREFOR | OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-09-18 | — | — | US | claimed |
| US-20250213727-A1 | DOMINANT-NEGATIVE TUMOR NECROSIS FACTOR ALPHA ADENO-ASSOCIATED VIRUS GENE THERAPY | REGENXBIO INC. | 2025-07-03 | — | — | US | claimed |
| US-12337063-B2 | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets | UNIVERSITY OF SHARJAH (AE) | 2025-06-24 | — | — | US | claimed |
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2025-06-12 | — | — | US | claimed |
| US-4952586-A | FOR ANTAGONIZING NONDEPOLARIZING NEUROMUSCULAR BLOCKADE WHEN MUSCLE RELAXATION IS NOT NEEDED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-08-28 | — | — | US | claimed |
| WO-1990004395-A1 | NOVEL ANTI-MICTURITION COMPOSITION AND METHOD | LEITMAN ESTHER M (US) | 1990-05-03 | — | — | WO | claimed |
| US-4906641-A | Anti-micturition composition and method | LEITMAN ESTHER M (US) | 1990-03-06 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4852582-A | Method and kit for measuring the effectiveness of bronchodilators | PELL DONALD M (US) | 1989-08-01 | — | — | US | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3965255-A | DRUG ENCAPSULATED IN OR COATED WITH A SOLVENT MEMBRANE | E. E. ELJIM ECOLOGY LTD. (IL) | 1976-06-22 | — | — | US | claimed |